Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

PB103

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Chongqing Precision Biotech

Drug class:

NK cell stimulant

Related drugs:

‹

dualCAR-NK19/70 (0)

m-ceNK cells (0)

pomalidomide (16)

AFM13/AB-101 (1)

cytotoxic lymphocyte-based cancer vaccine (0)

CAR-ITNK cells (0)

CAR-NK-CD19 cells (0)

CAR.70/IL15-transduced CB-NK cells (0)

CB CAR-NK019 (0)

CD123 targeted CAR-NK (0)

CD33/CLL1 dual CAR-NK cell (0)

CDH17 CAR-NK cell therapy (0)

CLDN6-CAR-NK cell therapy (0)

CYTO NK-102 (0)

DC vaccine for prostate cancer (0)

primed NK cell therapy (0)

Magicell-NK (0)

NK/γδ T cell-enriched cell therapy (0)

NK92-CD16-158V (0)

NKG2D CAR-NK cell therapy (0)

NKG2D-CAR-NK92 cells (0)

Super NK cell therapy (0)

TROP2-CAR-NK (0)

UD TGFbetai NK cells (0)

dualCAR-NK19/70 (0)

m-ceNK cells (0)

›

1year

Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients (clinicaltrials.gov)

P1/2, N=24, Recruiting, Precision Biotech Taiwan Corp. | Trial primary completion date: Jun 2022 --> Dec 2024

1 year ago

Trial primary completion date • Combination therapy

|

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

|

PB103